SCLX Stock Touches 52-Week Low at $0.33 Amid Market Challenges
In a turbulent market environment, SCLX stock has reached a 52-week low, trading at $0.33, with a market capitalization of $62.12 million. This price level reflects a significant downturn for the ...
pulmonologyadvisor16h
FDA Approves Symbravo for Acute Treatment of Migraine in Adults
The US FDA has approved Symbravo (meloxicam and rizatriptan) for the acute treatment of migraine with or without aura in adults.
El Mundo on MSN18h
US approves a new painkiller with less risk of addiction than opioids and equally potent
The suzetrigine, which only acts on pain neurons, is the first innovation in analgesia in the last 20 years. "It stands out ...